Faisal Khurshid, an analyst from Leerink Partners, reiterated the Buy rating on ANI Pharmaceuticals (ANIP – Research Report). The associated price target was raised to $85.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Faisal Khurshid has given his Buy rating due to a combination of factors including ANI Pharmaceuticals’ strong financial performance and strategic positioning. The company reported impressive first-quarter earnings with revenue and adjusted EBITDA exceeding consensus estimates, driven by the success of its generics segment and a new product launch. Additionally, ANI Pharmaceuticals raised its 2025 guidance for net revenues and adjusted EBITDA, reflecting confidence in its growth trajectory.
Furthermore, the company’s Cortrophin Gel is performing well, with a record number of new patient starts and continued growth in its unique indication for acute gouty arthritis. The management’s confidence in the ACTH class and the strategic positioning of Cortrophin Gel against competitors like Acthar Gel further supports the positive outlook. The initiation of a Phase IV study for Cortrophin Gel could enhance its recognition and usage, contributing to the company’s long-term growth potential.
In another report released yesterday, Raymond James also reiterated a Buy rating on the stock with a $86.00 price target.
Based on the recent corporate insider activity of 70 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ANIP in relation to earlier this year.